Virosomes-Hybrid Drug Delivery Systems
- *Corresponding Author:
- Alvina Gul Kazi
School of Applied Biosciences
National University of Sciences and Technology
E-mail: [email protected]
Received Date: October 28, 2013; Accepted Date: November 28, 2013; Published Date: December 02, 2013
Citation: Babar MM, Zaidi NSS, Kazi AG, Rehman A (2013) Virosomes-Hybrid Drug Delivery Systems. J Antivir Antiretrovir 5:166-172. doi: 10.4172/jaa.1000083
Copyright: © 2013 Babar MM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The development of safe and effective models for the delivery of any prophylactic or therapeutic agent remains an uphill task for pharmaceutical formulation developers. Drug molecules, nucleic acids, carbohydrates, proteins and a variety of other biological and chemical entities are used for attaining pharmacological benefits. However, the major challenge remains in the delivery of these agents to the specific site of action in a time-efficient manner. Among the many drug delivery systems developed, the nano scale technology of virosomes tends to present an established system of delivering the therapeutic agents to the site of pharmacological action. Virosomes are lipid bilayer, unilamellar structures that present viral protein on their surface. They are safe, biocompatible and biodegradable structures that can achieve ideal pharmacological profile once administered into the body. Tissue targeting, immune activation and potentiation are the chief advantages that make them efficient prophylactic and therapeutic agents. The review presents the biopharmaceutical applications of virosomes and the immunological and pharmaceutical considerations that make them efficient agents for targeting spatiotemporal parameters in the body.